| Drug consumption facilities in Europe and the establishment of supervised injecting centres in Australia K Dolan, Jo Kimber, Craig Fry, David McDonald, John Fitzgerald, Franz Trautmann Drug and alcohol review 19 (3), 337-346, 2000 | 229 | 2000 |
| For love or money? An exploratory study of why injecting drug users participate in research C Fry, R Dwyer Addiction 96 (9), 1319-1325, 2001 | 228 | 2001 |
| Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? RA Jenkinson, NC Clark, CL Fry, M Dobbin Addiction 100 (2), 197-205, 2005 | 171 | 2005 |
| Australian drug trends 2001: Findings of the illicit drug reporting system (IDRS) L Topp, S Kaye, RB Bruno, M Longo, P Williams, B O'Reilly, CL Fry, ... University of New South Wales, 2002 | 150 | 2002 |
| Transient changes in behaviour lead to heroin overdose: results from a case‐crossover study of non‐fatal overdose P Dietze, D Jolley, C Fry, G Bammer Addiction 100 (5), 636-642, 2005 | 97 | 2005 |
| Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia L Degenhardt, L Degenhardt, E Black, L Degenhardt, E Black, C Breen, ... Drug and Alcohol Review 25 (5), 403-412, 2006 | 94 | 2006 |
| The ethics of paying drug users who participate in research: a review and practical recommendations CL Fry, W Hall, A Ritter, R Jenkinson Journal of Empirical Research on Human Research Ethics 1 (4), 21-35, 2006 | 90 | 2006 |
| Paying research participants: a study of current practices in Australia CL Fry, A Ritter, S Baldwin, KJ Bowen, P Gardiner, T Holt, R Jenkinson, ... Journal of medical ethics 31 (9), 542-547, 2005 | 86 | 2005 |
| The ethics of reimbursing injecting drug users for public health research interviews: what price are we prepared to pay? AJ Ritter, CL Fry, A Swan International Journal of Drug Policy 14, 1-3, 2003 | 83 | 2003 |
| Victorian drug trends 2003: Findings from the illicit drug reporting system (IDRS) R Jenkinson, P Miller, CL Fry University of New South Wales, 2004 | 72* | 2004 |
| A survey of regular ecstasy users’ knowledge and practices around determining pill content and purity: Implications for policy and practice J Johnston, MJ Barratt, CL Fry, S Kinner, M Stoové, L Degenhardt, ... International Journal of Drug Policy 17 (6), 464-472, 2006 | 71 | 2006 |
| Ethical challenges and responses in harm reduction research: promoting applied communitarian ethics CL Fry, C Treloar, L Maher Drug and alcohol review 24 (5), 449-459, 2005 | 71 | 2005 |
| Drug and alcohol treatment providers’ views about the disease model of addiction and its impact on clinical practice: A systematic review AI Barnett, W Hall, CL Fry, E Dilkes‐Frayne, A Carter Drug and alcohol review 37 (6), 697-720, 2018 | 66 | 2018 |
| When is a little knowledge dangerous?: circumstances of recent heroin overdose and links to knowledge of overdose risk factors P Dietze, D Jolley, CL Fry, G Bammer, D Moore Drug and Alcohol Dependence 84 (3), 223-230, 2006 | 64 | 2006 |
| Establishing safe injecting rooms in Australia: attitudes of injecting drug users C Fry, S Fox, G Rumbold Australian and New Zealand Journal of Public Health 23 (5), 501-504, 1999 | 63 | 1999 |
| Realising the technological promise of smartphones in addiction research and treatment: an ethical review H Capon, W Hall, C Fry, A Carter International Journal of Drug Policy 36, 47-57, 2016 | 59 | 2016 |
| Intentional overdose among heroin overdose survivors P Heale, P Dietze, C Fry Journal of Urban Health 80 (2), 230-237, 2003 | 58 | 2003 |
| Ethical questions must be considered for electronic health records M Spriggs, MV Arnold, CM Pearce, C Fry Journal of Medical Ethics 38 (9), 535-539, 2012 | 56 | 2012 |
| Injecting drug user attitudes towards rules for supervised injecting rooms: Implications for uptake CL Fry International Journal of Drug Policy 13 (6), 471-476, 2002 | 53 | 2002 |
| Positive and negative aspects of participation in illicit drug research: implications for recruitment and ethical conduct MJ Barratt, JS Norman, CL Fry International Journal of Drug Policy 18 (3), 235-238, 2007 | 51 | 2007 |
